Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

Invitae Corp

Start price
Target price
Perf. (%)
€23.02
01.11.21
-
01.11.22
-87.22%
02.11.22

Probably not worthwhile Investment
buy
Davita Inc.

Start price
Target price
Perf. (%)
€73.02
28.10.22
-
0.45%
28.10.22

Risky Investment
buy
Molina Healthcare

Start price
Target price
Perf. (%)
€322.00
13.08.22
-
13.08.23
14.29%
25.10.22

buy
Tandem Diabetes Care Inc

Start price
Target price
Perf. (%)
€111.45
23.10.21
-
23.10.22
-50.65%
24.10.22

buy
Invitae Corp

Start price
Target price
Perf. (%)
€2.47
27.09.22
-
27.09.23
-13.02%
15.10.22

Risky Investment
buy
Invitae Corp

Start price
Target price
Perf. (%)
€2.26
10.10.22
-
10.10.23
-5.19%
15.10.22

buy
Acceleron Pharma Inc.

Start price
Target price
Perf. (%)
€158.00
28.09.21
-
28.09.22
0.63%
28.09.22

buy
Invitae Corp

Start price
Target price
Perf. (%)
€2.76
02.09.22
-
02.09.23
-10.51%
27.09.22

Could be very worthwhile Investment >20% year
buy
Invitae Corp

Start price
Target price
Perf. (%)
€2.75
04.09.22
-
04.09.23
-10.49%
27.09.22

buy
Tandem Diabetes Care Inc

Start price
Target price
Perf. (%)
€54.50
21.06.22
-
21.06.23
-7.34%
20.09.22

buy
Bluebird Bio Inc.

Start price
Target price
Perf. (%)
€7.10
12.09.22
-
12.09.23
-1.41%
17.09.22

Agios Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€32.00
03.09.22
€16.00
03.09.23
-3.75%
17.09.22

buy
Mirati Therapeutics Inc.

Start price
Target price
Perf. (%)
€76.50
21.08.22
€230.00
21.08.23
6.54%
04.09.22

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Probably not worthwhile Investment
Lower EBIT Margin than peer group
Invitae Corp

Start price
Target price
Perf. (%)
€3.50
21.08.22
€1.00
21.08.23
-21.28%
04.09.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Alnylam Pharmace.

Start price
Target price
Perf. (%)
€214.90
21.08.22
€87.00
21.08.23
-3.44%
04.09.22

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Invitae Corp

Start price
Target price
Perf. (%)
€3.32
26.08.22
-
26.08.23
-17.03%
03.09.22

Could be very worthwhile Investment >20% year
buy
Molina Healthcare

Start price
Target price
Perf. (%)
€247.40
20.10.21
€280.00
31.12.23
39.05%
01.09.22

Could be very worthwhile Investment >20% year
buy
Invitae Corp

Start price
Target price
Perf. (%)
€3.80
18.08.22
-
18.08.23
-7.92%
20.08.22

buy
Invitae Corp

Start price
Target price
Perf. (%)
€4.77
11.08.22
-
11.08.23
-26.65%
20.08.22

buy
Amn Healthcare Svs

Start price
Target price
Perf. (%)
€92.00
03.02.22
€115.00
03.02.23
11.96%
18.08.22

buy
Teladoc Health Inc

Start price
Target price
Perf. (%)
€39.58
15.07.22
-
15.08.22
-0.72%
15.08.22

Invitae Corp

Start price
Target price
Perf. (%)
€8.46
10.08.22
-
10.08.23
-48.25%
11.08.22

Risky Investment
buy
Tandem Diabetes Care Inc

Start price
Target price
Perf. (%)
€91.50
10.08.21
-
10.08.22
-42.25%
10.08.22

buy
Teladoc Health Inc

Start price
Target price
Perf. (%)
€41.45
07.07.22
-
07.08.22
-12.03%
08.08.22

buy
Global Blood Therapeutics Inc

Start price
Target price
Perf. (%)
€33.09
30.10.21
€45.00
31.12.23
94.65%
05.08.22

Could be very worthwhile Investment >20% year